Last reviewed · How we verify
Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin is a Antimalarial Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Treatment of uncomplicated malaria, Treatment of severe malaria.
Sulphadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while amodiaquine is an antimalarial drug that works by interfering with the parasite's ability to synthesize DNA and RNA.
Sulphadoxine-pyrimethamine is a combination of a sulfonamide antibiotic and a dihydrofolate reductase inhibitor, while amodiaquine is an antimalarial drug that works by interfering with the parasite's ability to synthesize DNA and RNA. Used for Treatment of uncomplicated malaria, Treatment of severe malaria.
At a glance
| Generic name | Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Sulphadoxine-pyrimethamine works by inhibiting the growth of the malaria parasite, while amodiaquine interferes with the parasite's ability to synthesize DNA and RNA, ultimately leading to the death of the parasite. The combination of these two drugs is used to treat malaria.
Approved indications
- Treatment of uncomplicated malaria
- Treatment of severe malaria
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin CI brief — competitive landscape report
- Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI
Frequently asked questions about Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin
What is Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin?
How does Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin work?
What is Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin used for?
Who makes Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin?
What drug class is Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin in?
What development phase is Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin in?
What are the side effects of Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin?
Related
- Drug class: All Antimalarial drugs
- Manufacturer: London School of Hygiene and Tropical Medicine — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of uncomplicated malaria
- Indication: Drugs for Treatment of severe malaria